Source:http://linkedlifedata.com/resource/pubmed/id/19061963
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2009-3-2
|
pubmed:abstractText |
Amyloid beta-protein (Abeta) in the brain of Alzheimer's disease (AD) plays a detrimental role in synaptic plasticity and cognitive function. The effects of Abeta on the early-phase long-term potentiation (E-LTP) have been reported widely. However, whether the late-phase long-term potentiation (L-LTP), which differs from E-LTP mechanistically, is also affected by Abeta is still an open question. The present study examined the effects of intracerebraventricular injection of Abeta fragments 25-35 and 31-35 on the L-LTP in the CA1 area of rat hippocampus in vivo, and further investigated its possible underlying mechanism. Our results showed that: (1) Abeta25-35 (6.25-25 nmol) did not affect the baseline field excitatory postsynaptic potentials, but dose-dependently suppressed multiple high-frequency stimuli-induced L-LTP; (2) Abeta31-35, a shorter Abeta fragment than Abeta25-35, also significantly suppressed L-LTP, with the same suppressive effects as Abeta25-35; (3) pretreatment with PMA (6 nmol/5 microl), a membrane permeable PKC agonist, effectively prevented Abeta31-35-induced deficits in the early and the late components of L-LTP; (4) co-application of Abeta31-35 and chelerythrine (12 nmol/5 microl), a PKC antagonist, caused no additive suppression of L-LTP. These results indicate that both Abeta25-35 and Abeta31-35 can impair hippocampal synaptic plasticity in vivo by suppressing the maintenance of L-LTP, and PKC probably mediates the Abeta-induced suppression of hippocampal L-LTP. In addition, the similar efficacy of Abeta31-35 and Abeta25-35 in L-LTP suppression supports the hypothesis we suggested previously that the sequence 31-35 in Abeta might be the shortest active sequence responsible for the neuronal toxicity induced by full length of Abeta molecules.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Amyloid beta-Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/Benzophenanthridines,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Activators,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase C,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Tetradecanoylphorbol Acetate,
http://linkedlifedata.com/resource/pubmed/chemical/amyloid beta-protein (25-35),
http://linkedlifedata.com/resource/pubmed/chemical/amyloid beta-protein (31-35),
http://linkedlifedata.com/resource/pubmed/chemical/chelerythrine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
1095-9564
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
91
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
226-34
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:19061963-Amyloid beta-Peptides,
pubmed-meshheading:19061963-Animals,
pubmed-meshheading:19061963-Benzophenanthridines,
pubmed-meshheading:19061963-Electrodes, Implanted,
pubmed-meshheading:19061963-Enzyme Activators,
pubmed-meshheading:19061963-Excitatory Postsynaptic Potentials,
pubmed-meshheading:19061963-Hippocampus,
pubmed-meshheading:19061963-Long-Term Potentiation,
pubmed-meshheading:19061963-Male,
pubmed-meshheading:19061963-Peptide Fragments,
pubmed-meshheading:19061963-Protein Kinase C,
pubmed-meshheading:19061963-Protein Kinase Inhibitors,
pubmed-meshheading:19061963-Rats,
pubmed-meshheading:19061963-Rats, Wistar,
pubmed-meshheading:19061963-Tetradecanoylphorbol Acetate
|
pubmed:year |
2009
|
pubmed:articleTitle |
Protein kinase C mediates amyloid beta-protein fragment 31-35-induced suppression of hippocampal late-phase long-term potentiation in vivo.
|
pubmed:affiliation |
Department of Neurobiology and National Key Discipline of Physiology, Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|